Navigation Links
Biotech collaboration established to commercialize research reagents
Date:10/18/2010

The Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, has entered a collaboration with New Jersey-based medical technology company BD to evaluate and potentially develop for research and diagnostic use some of the institute's reagents.

The institute has a portfolio of more than 100 monoclonal antibodies produced through its in-house antibody facility for research into cancer, chronic inflammatory diseases and infectious diseases.

The collaboration, with BD's Biosciences segment, will build on programs at the institute that are focused on identifying novel targets for therapeutic monoclonal antibody and drug development.

Under the terms of the agreement, BD will make upfront and annual payments to the institute as well as royalty payments on sales of any licensed antibodies in return for a first option to evaluate and commercialise antibodies from the institute. The financial terms of the collaboration are confidential.

The institute's business development manager Dr James Dromey said antibodies were an important tool in the lab as well as the clinic, where they are used as diagnostic tools and biomarkers.

"This is a wonderful opportunity for the institute to share its internal resources and scientific expertise with the wider scientific community and to improve the possibility of the institute's technology being commercialised and having a positive impact on research and diagnostic markets," Dr Dromey said.

"The institute's strategic research interests align well with those of BD, particularly in key areas such as cancer, programmed cell death (apoptosis), stem cells and immunology. This is the first commercial contract that we have established for wider utilisation of institute reagents, and we hope it will be the first step in a broader collaboration with BD."

The institute has a track record for producing commercially available and successful products, including the LIF protein, which is essential for the maintenance of embryonic stem cells, and the pGex fusion protein vector.

Antibody production and related services form one of the most important technology platforms that underpin the institute's successful science and commercialisation activities. The institute's 'discovery pipeline' is fed by more than 250 research projects, many involving development of new antibodies through its in-house antibody facility.


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Related biology news :

1. Developments in nanobiotechnology at UCSB point to medical applications
2. New biotech company grows from MCG diabetes and genomic research
3. $31 million biotech center to benefit crops, food, energy
4. Success with cisgenics in forestry offers new tools for biotechnology
5. Cutting-edge vaccine research to be showcased at AAPS National Biotechnology Conference
6. Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference
7. AAPS immunogenicity training course to be offered prior to national biotechnology conference
8. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
9. NYU School of Medicine presents biomedical researchers Dart/NYU Biotechnology Achievement Awards
10. GenWay Biotech extends the You Test You program overseas
11. New biotech advance to add heart healthy omega-3s to US diet
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biotech collaboration established to commercialize research reagents
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:5/3/2016)... May 3, 2016 - And ... and Producers of Those Competitor Biologics  - ... Activities and Prospects ,  Who are the ... And what are their sales potentials? Discover, in our ... results, trends, opportunities and revenue forecasting. ...
(Date:5/2/2016)... 2016 Q BioMed Inc. (QBIO), ... Mannin Research Inc. will be attending the Association for ... from May 1-5, 2016 in Seattle Washington ... its vendors and research partners. The meeting provides organizations ... other collaborative opportunities for the MAN-01 program for treatment ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design ... the bioLogic team explored how bacterial properties can be applied to fabric and formed ... bacteria, which move in response to humidity change. The team harvested Natto cells and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... necessary fundamentals to transform technology into a viable company, CereScan’s CEO, John Kelley, ... Mr. Kelley, a recognized leader and mentor in the Denver area business community, ...
Breaking Biology Technology: